Dapagliflozin, peptide YY, and weight loss in heart failure with preserved ejection fraction-Reference-Cited by-同舟云学术

Dapagliflozin, peptide YY, and weight loss in heart failure with preserved ejection fraction

Published:2024-08-21 Issue: Volume: Page:
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:

Author:

Reddy Yogesh N V¹^ORCID,Melenovsky Vojtech²^ORCID,Asokan Aneesh K³,Haluzik Martin²,Carter Rickey E⁴,Nair Sreekumaran³,Jensen Michael D³,Borlaug Barry A¹^ORCID

Affiliation:

1. The Department of Cardiovascular Medicine, Mayo Clinic , 200 First Street SW, Rochester, MN, USA

2. Institute for Clinical and Experimental Medicine (IKEM) , Prague , Czech Republic

3. Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Mayo Clinic , Rochester, MN, USA

4. Department of Quantitative Health Sciences, Division of Clinical Trials & Biostatistics, Mayo Clinic , Jacksonville, FL, USA

Funder

AstraZeneca

National Heart, Lung and Blood Institute

United States Department of Defense

Czech National Institute for Research of Metabolic and Cardiovascular Diseases

European Union—Next Generation EU

National Heart, Lung, And Blood Institute

Bayer

United pharmaceuticals

Mayo Clinic

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/eurheartj/advance-article-pdf/doi/10.1093/eurheartj/ehae534/58881443/ehae534.pdf

Reference10 articles.

1. Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes;Packer;Circulation,2023

2. Dapagliflozin for heart failure according to body mass index: the DELIVER trial;Adamson;Eur Heart J,2022

3. Effects of dapagliflozin on body composition and its relation to hemodynamics in heart failure with preserved ejection fraction;Naser;Circulation,2024

4. Cardiac and metabolic effects of dapagliflozin in heart failure with preserved ejection fraction: the CAMEO-DAPA trial;Borlaug;Circulation,2023

5. Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme;Zannad;Eur Heart J,2022